Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Antiproteinuric treatment reduces urinary loss of vitamin D-binding protein but does not affect vitamin D status in patients with chronic kidney disease.

Doorenbos CR, de Cuba MM, Vogt L, Kema IP, van den Born J, Gans RO, Navis G, de Borst MH.

J Steroid Biochem Mol Biol. 2012 Jan;128(1-2):56-61. doi: 10.1016/j.jsbmb.2011.09.002. Epub 2011 Sep 21.

PMID:
21958677
2.

Indomethacin reduces glomerular and tubular damage markers but not renal inflammation in chronic kidney disease patients: a post-hoc analysis.

de Borst MH, Nauta FL, Vogt L, Laverman GD, Gansevoort RT, Navis G.

PLoS One. 2012;7(5):e37957. doi: 10.1371/journal.pone.0037957. Epub 2012 May 25.

3.

Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade.

Humalda JK, Lambers Heerspink HJ, Kwakernaak AJ, Slagman MC, Waanders F, Vervloet MG, Ter Wee PM, Navis G, de Borst MH; NIGRAM Consortium.

Am J Kidney Dis. 2015 Feb;65(2):259-66. doi: 10.1053/j.ajkd.2014.07.022. Epub 2014 Sep 30.

PMID:
25278093
4.

Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.

Luño J, Barrio V, Goicoechea MA, González C, de Vinuesa SG, Gómez F, Bernis C, Espinosa M, Ahijado F, Gómez J, Escalada P.

Kidney Int Suppl. 2002 Dec;(82):S47-52.

5.

Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.

Agarwal R, Siva S, Dunn SR, Sharma K.

Am J Kidney Dis. 2002 Mar;39(3):486-92.

PMID:
11877567
6.

Vitamin D Binding Protein Is Not Involved in Vitamin D Deficiency in Patients with Chronic Kidney Disease.

Kalousova M, Dusilova-Sulkova S, Zakiyanov O, Kostirova M, Safranek R, Tesar V, Zima T.

Biomed Res Int. 2015;2015:492365. doi: 10.1155/2015/492365. Epub 2015 May 4.

7.

Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial.

Waanders F, Vaidya VS, van Goor H, Leuvenink H, Damman K, Hamming I, Bonventre JV, Vogt L, Navis G.

Am J Kidney Dis. 2009 Jan;53(1):16-25. doi: 10.1053/j.ajkd.2008.07.021. Epub 2008 Sep 27.

8.

Selective cyclooxygenase-2 (COX-2) inhibition reduces proteinuria in renal patients.

Vogt L, de Zeeuw D, Woittiez AJ, Navis G.

Nephrol Dial Transplant. 2009 Apr;24(4):1182-9. doi: 10.1093/ndt/gfn644. Epub 2008 Nov 26.

PMID:
19037084
9.

[The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? ].

Morales E, Huerta A, Gutiérrez E, Gutiérrez Solís E, Segura J, Praga M.

Nefrologia. 2009;29(5):421-9. doi: 10.3265/Nefrologia.2009.29.5.5448.en.full. Spanish.

11.

Late escape from the antiproteinuric effect of ace inhibitors in nondiabetic renal disease.

Shiigai T, Shichiri M.

Am J Kidney Dis. 2001 Mar;37(3):477-83.

PMID:
11228170
12.

Enhanced excretion of vitamin D binding protein in type 1 diabetes: a role in vitamin D deficiency?

Thrailkill KM, Jo CH, Cockrell GE, Moreau CS, Fowlkes JL.

J Clin Endocrinol Metab. 2011 Jan;96(1):142-9. doi: 10.1210/jc.2010-0980. Epub 2010 Oct 13.

13.

Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.

Esnault VL, Ekhlas A, Nguyen JM, Moranne O.

Nephrol Dial Transplant. 2010 Jul;25(7):2218-24. doi: 10.1093/ndt/gfp776. Epub 2010 Jan 26.

PMID:
20106824
14.

Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.

Catapano F, Chiodini P, De Nicola L, Minutolo R, Zamboli P, Gallo C, Conte G.

Am J Kidney Dis. 2008 Sep;52(3):475-85. doi: 10.1053/j.ajkd.2008.03.008. Epub 2008 May 12.

PMID:
18468748
15.

Effects of antiproteinuric intervention on elevated connective tissue growth factor (CTGF/CCN-2) plasma and urine levels in nondiabetic nephropathy.

Slagman MC, Nguyen TQ, Waanders F, Vogt L, Hemmelder MH, Laverman GD, Goldschmeding R, Navis G.

Clin J Am Soc Nephrol. 2011 Aug;6(8):1845-50. doi: 10.2215/CJN.08190910. Epub 2011 Jul 22.

16.

Urinary Vitamin D Binding Protein and KIM-1 Are Potent New Biomarkers of Major Adverse Renal Events in Patients Undergoing Coronary Angiography.

Chaykovska L, Heunisch F, von Einem G, Alter ML, Hocher CF, Tsuprykov O, Dschietzig T, Kretschmer A, Hocher B.

PLoS One. 2016 Jan 11;11(1):e0145723. doi: 10.1371/journal.pone.0145723. eCollection 2016.

17.

25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system.

Fernández-Juárez G, Luño J, Barrio V, de Vinuesa SG, Praga M, Goicoechea M, Lahera V, Casas L, Oliva J; PRONEDI Study Group.

Clin J Am Soc Nephrol. 2013 Nov;8(11):1870-6. doi: 10.2215/CJN.00910113. Epub 2013 Oct 17.

18.

[Antiproteinuric effect of renin-angiotensin system blockade in patients with normal/lower than 115 mmHg systolic blood pressure].

Gutiérrez E, González E, Morales E, Herrero JC, Manzanera MJ, García JA, Domínguez-Gil B, Hernández E, Praga M.

Nefrologia. 2004;24(6):546-52. Spanish.

19.

Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study.

Renke M, Tylicki L, Rutkowski P, Knap N, Zietkiewicz M, Neuwelt A, Aleksandrowicz E, Łysiak-Szydłowska W, Woźniak M, Rutkowski B.

Acta Biochim Pol. 2010;57(1):119-23. Epub 2010 Mar 22.

20.

ACE DD genotype is more susceptible than ACE II and ID genotypes to the antiproteinuric effect of ACE inhibitors in patients with proteinuric non-insulin-dependent diabetes mellitus.

Ha SK, Yong Lee S, Su Park H, Ho Shin J, Jung Kim S, Hun Kim D, Rae Kim K, Yung Lee H, Suk Han D.

Nephrol Dial Transplant. 2000 Oct;15(10):1617-23.

PMID:
11007831

Supplemental Content

Support Center